Selected research
Industry Growth & Trends
Global AI Drug Discovery Software Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global AI Drug Discovery Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for AI Drug Discovery Software is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for AI Drug Discovery Software is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AI Drug Discovery Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the AI Drug Discovery Software market include Merck KGaA, Atomwise Inc, BenevolentAI, BullFrog AI, Genesis Therapeutics, Pharma.AI, Recursion Pharmaceuticals, Verge Genomics and Schrödinger, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global AI Drug Discovery Software market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The AI Drug Discovery Software market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global AI Drug Discovery Software market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to AI Drug Discovery Software.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global AI Drug Discovery Software market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
AI Drug Discovery Software Market by Company
Merck KGaA
Atomwise Inc
BenevolentAI
BullFrog AI
Genesis Therapeutics
Pharma.AI
Recursion Pharmaceuticals
Verge Genomics
Schrödinger, Inc.
XtalPi
Iktos
AI Drug Discovery Software Segment by Type
Cloud Based
On Premise
AI Drug Discovery Software Segment by Application
CRO and Universities
Pharmaceutical Company
Test Lab
AI Drug Discovery Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Drug Discovery Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI Drug Discovery Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Drug Discovery Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of AI Drug Discovery Software companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud Based
- On Premise
Applications
- CRO and Universities
- Pharmaceutical Company
- Test Lab
Companies covered
- Merck KGaA
- Atomwise Inc
- BenevolentAI
- BullFrog AI
- Genesis Therapeutics
- Pharma.AI
- Recursion Pharmaceuticals
- Verge Genomics
- Schrödinger, Inc.
- XtalPi
- Iktos
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global AI Drug Discovery Software Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global AI Drug Discovery Software Market Size by Region (2021-2032)
- 1.4.1 Global AI Drug Discovery Software Market Size by Region (2021-2026)
- 1.4.2 Global AI Drug Discovery Software Market Size by Region (2027-2032)
- 1.5 Key Regions AI Drug Discovery Software Market Size (2021-2032)
- 1.5.1 North America AI Drug Discovery Software Market Size Growth Rate (2021-2032)
- 1.5.2 Europe AI Drug Discovery Software Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific AI Drug Discovery Software Market Size Growth Rate (2021-2032)
- 1.5.4 South America AI Drug Discovery Software Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa AI Drug Discovery Software Market Size Growth Rate (2021-2032)
2 AI Drug Discovery Software Market by Type
- 2.1 Type Introduction
- 2.1.1 Cloud Based
- 2.1.2 On Premise
- 2.2 Global AI Drug Discovery Software Market Size by Type
- 2.2.1 Global AI Drug Discovery Software Market Size Overview by Type (2021-2032)
- 2.2.2 Global AI Drug Discovery Software Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global AI Drug Discovery Software Market Size Forecasted by Type (2027-2032)
- 2.3 Global AI Drug Discovery Software Market Size by Regions
- 2.3.1 North America AI Drug Discovery Software Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe AI Drug Discovery Software Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific AI Drug Discovery Software Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America AI Drug Discovery Software Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa AI Drug Discovery Software Market Size Breakdown by Type (2021-2026)
3 AI Drug Discovery Software Market by Application
- 3.1 Type Introduction
- 3.1.1 CRO and Universities
- 3.1.2 Pharmaceutical Company
- 3.1.3 Test Lab
- 3.2 Global AI Drug Discovery Software Market Size by Application
- 3.2.1 Global AI Drug Discovery Software Market Size Overview by Application (2021-2032)
- 3.2.2 Global AI Drug Discovery Software Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global AI Drug Discovery Software Market Size Forecasted by Application (2027-2032)
- 3.3 Global AI Drug Discovery Software Market Size by Regions
- 3.3.1 North America AI Drug Discovery Software Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe AI Drug Discovery Software Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific AI Drug Discovery Software Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America AI Drug Discovery Software Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa AI Drug Discovery Software Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 AI Drug Discovery Software Industry Trends
- 4.2 AI Drug Discovery Software Industry Drivers
- 4.3 AI Drug Discovery Software Industry Opportunities and Challenges
- 4.4 AI Drug Discovery Software Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by AI Drug Discovery Software Revenue (2021-2026)
- 5.2 Global AI Drug Discovery Software Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global AI Drug Discovery Software Key Company Headquarters & Area Served
- 5.4 Global AI Drug Discovery Software Company, Product Type & Application
- 5.5 Global AI Drug Discovery Software Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global AI Drug Discovery Software Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 AI Drug Discovery Software Players Market Share by Revenue in 2025
- 5.6.3 2025 AI Drug Discovery Software Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Merck KGaA
- 6.1.1 Merck KGaA Company Information
- 6.1.2 Merck KGaA Business Overview
- 6.1.3 Merck KGaA AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Merck KGaA AI Drug Discovery Software Product Portfolio
- 6.1.5 Merck KGaA Recent Developments
- 6.2 Atomwise Inc
- 6.2.1 Atomwise Inc Company Information
- 6.2.2 Atomwise Inc Business Overview
- 6.2.3 Atomwise Inc AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Atomwise Inc AI Drug Discovery Software Product Portfolio
- 6.2.5 Atomwise Inc Recent Developments
- 6.3 BenevolentAI
- 6.3.1 BenevolentAI Company Information
- 6.3.2 BenevolentAI Business Overview
- 6.3.3 BenevolentAI AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 BenevolentAI AI Drug Discovery Software Product Portfolio
- 6.3.5 BenevolentAI Recent Developments
- 6.4 BullFrog AI
- 6.4.1 BullFrog AI Company Information
- 6.4.2 BullFrog AI Business Overview
- 6.4.3 BullFrog AI AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 BullFrog AI AI Drug Discovery Software Product Portfolio
- 6.4.5 BullFrog AI Recent Developments
- 6.5 Genesis Therapeutics
- 6.5.1 Genesis Therapeutics Company Information
- 6.5.2 Genesis Therapeutics Business Overview
- 6.5.3 Genesis Therapeutics AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Genesis Therapeutics AI Drug Discovery Software Product Portfolio
- 6.5.5 Genesis Therapeutics Recent Developments
- 6.6 Pharma.AI
- 6.6.1 Pharma.AI Company Information
- 6.6.2 Pharma.AI Business Overview
- 6.6.3 Pharma.AI AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pharma.AI AI Drug Discovery Software Product Portfolio
- 6.6.5 Pharma.AI Recent Developments
- 6.7 Recursion Pharmaceuticals
- 6.7.1 Recursion Pharmaceuticals Company Information
- 6.7.2 Recursion Pharmaceuticals Business Overview
- 6.7.3 Recursion Pharmaceuticals AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Recursion Pharmaceuticals AI Drug Discovery Software Product Portfolio
- 6.7.5 Recursion Pharmaceuticals Recent Developments
- 6.8 Verge Genomics
- 6.8.1 Verge Genomics Company Information
- 6.8.2 Verge Genomics Business Overview
- 6.8.3 Verge Genomics AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Verge Genomics AI Drug Discovery Software Product Portfolio
- 6.8.5 Verge Genomics Recent Developments
- 6.9 Schrödinger, Inc.
- 6.9.1 Schrödinger, Inc. Company Information
- 6.9.2 Schrödinger, Inc. Business Overview
- 6.9.3 Schrödinger, Inc. AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Schrödinger, Inc. AI Drug Discovery Software Product Portfolio
- 6.9.5 Schrödinger, Inc. Recent Developments
- 6.10 XtalPi
- 6.10.1 XtalPi Company Information
- 6.10.2 XtalPi Business Overview
- 6.10.3 XtalPi AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 XtalPi AI Drug Discovery Software Product Portfolio
- 6.10.5 XtalPi Recent Developments
- 6.11 Iktos
- 6.11.1 Iktos Company Information
- 6.11.2 Iktos Business Overview
- 6.11.3 Iktos AI Drug Discovery Software Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Iktos AI Drug Discovery Software Product Portfolio
- 6.11.5 Iktos Recent Developments
7 North America
- 7.1 North America AI Drug Discovery Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America AI Drug Discovery Software Market Size by Country (2021-2026)
- 7.3 North America AI Drug Discovery Software Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe AI Drug Discovery Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe AI Drug Discovery Software Market Size by Country (2021-2026)
- 8.3 Europe AI Drug Discovery Software Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific AI Drug Discovery Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific AI Drug Discovery Software Market Size by Country (2021-2026)
- 9.3 Asia-Pacific AI Drug Discovery Software Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America AI Drug Discovery Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America AI Drug Discovery Software Market Size by Country (2021-2026)
- 10.3 South America AI Drug Discovery Software Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa AI Drug Discovery Software Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa AI Drug Discovery Software Market Size by Country (2021-2026)
- 11.3 Middle East & Africa AI Drug Discovery Software Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst